Comparative Pharmacology
Head-to-head clinical analysis: DUOBRII versus HC 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUOBRII versus HC 1.
DUOBRII vs HC #1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Duobrii (halobetasol propionate and tazarotene) is a combination of a corticosteroid and a retinoid. Halobetasol propionate is a high-potency corticosteroid that acts via glucocorticoid receptors to induce anti-inflammatory, antiproliferative, and immunosuppressive effects. Tazarotene is a retinoid prodrug that is converted to its active form, tazarotenic acid, which binds to retinoic acid receptors (RAR-β, RAR-γ) to modulate gene expression, thereby reducing keratinocyte proliferation and promoting differentiation.
Unknown
Apply a thin layer to affected areas of the scalp once daily for 8 weeks. For external use only.
Hydrocortisone: 100-200 mg IV as initial dose, then 50-100 mg IV every 6 hours, or 0.18 mg/kg/h IV continuous infusion.
None Documented
None Documented
Halobetasol propionate: 7.5 hours (terminal); Tazarotene: 9-12 hours (terminal).
2–4 hours (terminal); prolonged in renal impairment.
Halobetasol propionate: 60% renal, 40% fecal; Tazarotene: <1% renal, 93% fecal, 6% biliary.
Renal: 90% as unchanged drug; fecal: 10%.
Category C
Category C
Topical Corticosteroid/Retinoid Combination
Topical Corticosteroid